



Health and Welfare
Canada

Santé et Bien-être social
Canada

Health Protection
Branch

Direction générale de la
protection de la santé

Bureau of Chemical Safety
4th Floor East
Sir Frederick Banting Bldg.
Tunney's Pasture
Ottawa, Ontario
K1A 0L2

September 18, 1990

Mr. W.C. Bachtel
Toxicologist
The BF Goodrich Company
3925 Embassy Parkway
Akron, Ohio 44313-1799
USA

Dear Dr. Bachtel:

RE: Geon 121

This has reference to your letter of June 12, 1990 wherein you submitted additional information on the sodium alpha olefin sulfonate component of the subject PVC resin on behalf of Cryovac Division, W.R. Grace & Co. of Canada Ltd.

The details submitted are adequate for our purposes and will enable us to proceed with our evaluation of your customer's submission. You may be assured that the information provided will be used in confidence for our assessment purposes only.

On behalf on the Health Protection Branch, our thanks for your co-operation in this matter.

Yours truly,

Michel A. Pelletier,
Food Packaging Materials and
Incidental Additives Section,
Chemical Evaluation Division.

Canada

BFG07547

20862001

AD-4188
dated



THE DOW CHEMICAL COMPANY

MIDLAND, MICHIGAN 48674

1803 BUILDING
July 3, 1990

REC'D AUG 13 1990

Ms. Barbara Cook
Project Manager
California Air Resources Board
1102 Q Street
Sacramento, CA 95814

Dear Ms. Cook:

Attached are our comments on the unit risk derivation presented in the May, 1990 Draft Technical Support Document, Proposed Identification of Vinyl Chloride as a Toxic Air Contaminant.

We appreciate your accepting our comments, which have been submitted to promote the best possible science in the performance of health risk assessments.

Please call on us should you require additional information.

Sincerely,

A handwritten signature in black ink, appearing to read "Neil C. Hawkins".

Neil C. Hawkins, Sc.D.
Senior Research Risk Analyst
Health and Environmental Sciences
1803 Building
(517) 636-8237

kal

Attachments

BFG07548

20863001

COMMENT: DRAFT TECHNICAL SUPPORT DOCUMENT, MAY, 1990,
"PROPOSED IDENTIFICATION OF VINYL CHLORIDE AS A TOXIC AIR
CONTAMINANT"

Derivation of a unit risk for Vinyl Chloride (CAS 75-01-4)

VCM is clearly a rat and human carcinogen, causing liver angiosarcoma in both species and zymbal gland tumors in rats. Thus, for regulatory purposes, there is interest in deriving a quantitative estimate of a level of no significant risk. There are two general approaches to this problem. One approach has been the use of safety factors or uncertainty factors applied to no-observed-effect-levels (NOEL's) in animals to derive a safe level in humans. The other general approach, which has been used more recently by regulatory agencies, has been the use of quantitative risk assessment to estimate levels of risk for any given exposure. The risk assessment process involves a number of decision points for which there is no scientific consensus as to the correct approach. These areas of uncertainty, including the presence or absence of thresholds, the shape of the dose response model, and animal to man conversion factors, have been resolved within the agencies through the use of policy decisions as to a default methodology. The default methodology is conservative in nature, so as to protect public health. However, the State of California Cancer Risk Assessment Guidelines as well as EPA and OSTP guidelines on the use of risk assessment clearly state that the default methodology should not be used when other data are available. In particular, epidemiology data and pharmacokinetic information should be incorporated into risk assessment when the appropriate data are available. The DHS unit risk for vinyl chloride of 20×10^{-5} per ppb, as cited in the CARB Draft Technical Document (CARB, 1990), does not utilize the available pharmacokinetic or epidemiological information.

Pharmacokinetic Information

Pharmacokinetic (PK) information can be used in two ways to augment risk assessments for vinyl chloride. PK data have been used to demonstrate and explain nonlinear behavior at both the high dose and low dose portions of the dose-response curve. The bioassay data of Maltoni (1979) clearly indicated a plateau in the dose-response curve at high doses. This phenomenon can be explained by the use of a Michaelis-Menton function to calculate metabolite concentrations, as suggested by Watanabe *et al.* (1976), and implemented by Gehring *et al.* (1978), Crump (1982) and USEPA (1987). However, this methodology only explains the high-dose results in the animal bioassay rather than addressing the problem of low-dose extrapolation. Low-dose risk assessments utilizing PK data have been discussed by Gehring *et al.* (1979) and Anderson *et al.* (1980).

Purchase *et al.* (1980) reviewed risk assessments for VCM and showed that, among the linear models used, risk estimates varied from the current DHS value, (equivalent to a unit risk of 20×10^{-5} per ppb), upwards (less risk) at least a factor of 100-fold. The different values derived from animal models vary primarily on the basis of whether or not pharmacokinetic information has been utilized in the assessment. In evaluating the use of pharmacokinetic data, Anderson *et al.* (1980) conclude that: "Based on the present understanding of the mechanism of carcinogenesis, we believe this to be a more rational approach to the low-dose extrapolation problem."

Gehring *et al.* (1979) fit a number of extrapolation models to the metabolized dose of VCM, and showed that risk estimates derived without consideration of low-dose metabolite formation potentially overestimate risk by at least an order of magnitude. For example, the one-hit model applied to metabolized dose predicts a risk of 189 per million at 1 ppm for an occupational exposure (Gehring, 1979). By comparison, use of nominal dose (air concentration), predicts upper bound "risks" of 37,000 per million using the unit risk of 20×10^{-5} per ppb. Other viable dose response models predict much lower risk.

Notwithstanding the fact that the health criteria represent one aspect of many inputs considered in the standard setting process, we submit it is essential to base any proposed regulation on the most complete information possible. For this reason we believe that risk assessments for vinyl chloride should include PK data, or preferably, the use of actual human data.

Risk assessments derived from epidemiology data

In the early 1970's, vinyl chloride was reported to cause a rare form of cancer, angiosarcoma of the liver, among workers who had been exposed at extremely high levels for many years in polyvinyl chloride (PVC) polymerization plants. Since this discovery, there have been approximately 50 angiosarcoma of the liver deaths reported throughout the United States and Canada which have been associated with previous vinyl chloride exposure. Eighty percent of these deaths occurred in four PVC plants where exposures to vinyl chloride were known to have been over 500 ppm in the 1950's and 1960's. Today, there are strict emission limitations under the NESHAP regulation, and the OSHA regulated 8-hour time weighted average for vinyl chloride is 1 ppm. It is particularly noteworthy that there has never been a reported death from angiosarcoma of the liver among Louisiana chemical workers who have worked with vinyl chloride.

Vinyl chloride has not been shown to cause cancer at any other anatomical site in humans. Epidemiologic studies conducted in the 1970's suggested that there may be an association with brain and lung cancer, however, recent updates of these studies have reported either no association, or associations only at a much lower statistical level of significance.

BFG07550

20863003

A world-recognized expert in epidemiology, Sir Richard Doll, recently reviewed the existing vinyl chloride literature as it pertains to cancer in humans. He concluded that vinyl chloride is a known occupational carcinogen (only for angiosarcoma of the liver) which is due to high occupational exposure levels which have not existed since this association was reported in the early 1970's. According to Doll, the risk for cancer in communities surrounding vinyl chloride production plants from environmental emissions in today's tightly controlled and well-regulated environment "must be negligible." (Doll, 1988)

Generally, risk assessments utilize animal data as the basis for quantification of risk. Human epidemiology data often do not have sufficiently precise exposure estimates or sufficiently well-defined populations to be of quantitative value. Human results are clearly preferred, when available, however, and should be included in any risk assessment review. In the case of VCM there are at least three assessments of sufficient precision which utilize the human database to estimate risk. In one analysis (Barr, 1982), negative epidemiological studies of people living near VCM production facilities have been used to estimate human potency. Barr estimates that 100 ppb is the approximate lifetime dose corresponding to a human risk of 10^{-6} . Purchase *et al.* (1987) note that Barr's estimate is similar to the highest estimates of 10^{-6} dose levels derived from animal data and are orders of magnitude higher than the conservative dose estimates which do not take into account low dose PK. This result is consistent with other observations that humans may be less sensitive than animals to the carcinogenic effects of VCM.

Gehring *et al.* (1979) compared the results of an epidemiological study of approximately 10,000 occupationally exposed workers to the values predicted by four different mathematical models derived from animal data. They conclude that the observed human results are inconsistent with the two linear non-threshold models used, and are consistent with both the probit model and a linear threshold model. The latter two models predict 10^{-6} risk levels at occupational exposure levels in excess of 1 ppm.

These analyses by no means prove the validity of the two models and undoubtedly numerous other models would fit and give quite different results for predicting the ambient level corresponding to a 10^{-6} risk level. However, these analyses do show that human epidemiology data can be used to derive risk estimates for VCM exposures and that the models indicate that the linear non-threshold models are conservative by a substantial margin. This is to be expected in light of the well known conservativeness of the models. U.S. EPA, for instance, when presenting risks estimates describes them as upper bounds and notes that: "the true value of the risk is unknown and may be as low as zero" (Federal Register, 1986).

In an analysis of alternative modeling assumptions for animal to human extrapolation, Elizabeth Anderson, (1984) as head of the U.S. EPA Cancer

155/0004 BFG07551 20863004

Assessment Group found that alternative plausible modeling assumptions would lead to risk estimates that were 15-fold to 10,000-fold lower than the standard LMS procedure. Thus it is essential to use the available human data to place some perspective on the results predicted solely from animal data.

In an independent review of VCM, the National Health Council of the Netherlands (1987) derived ambient exposure levels corresponding to risk levels of $10(-6)$ in humans. Their estimates were derived from both animal data and from epidemiological human data. While noting that the estimates did not differ greatly, they expressed a preference for the human data and reported a value of $1 \mu\text{g}/\text{cubic meter}$ as corresponding to a risk of $10(-6)$. This value is approximately 80 times higher than the exposure level derived using the DHS unit risk of $20 \times 10(-5)$ per ppb.

The over prediction of the models can be further demonstrated for VCM by comparing predictions of risk utilizing the DHS unit risk with human exposure scenarios. To make this comparison, Table 1 shows the "risk" predicted from the DHS model for a number of occupational exposure situations. The relevance of the specific exposure scenarios are also discussed below.

The specific exposure scenarios used in Table 1 were based upon a retrospective study (Barnes, 1976), in which past typical VCM exposures in PVC plants were estimated as: 1000 ppm in 1945-1955, 400-500 ppm in 1955-1960, 300-400 ppm in 1960-1970, 150 ppm in mid-1973 and considerably lower afterwards. Considering the latency of carcinogenesis in general, and for VCM in particular, tumor incidence rates noted in the 1980's reflect exposures from the 1960's.

It can be seen from Table 1 that incidence rates predicted from the linear animal model are completely incompatible with that observed in actual human studies. For example, in the study examined by Gehring (1970) there were only 5 observed cases in 9677 workers. This is approximately three orders of magnitude less than that which would be predicted by the DHS model.

Thus, there are a number of assessments based upon human epidemiological data which would indicate that linear models utilizing animal data overpredict risk by at least one to two orders of magnitude. In the interests of assuring that any proposed regulation is supported by as comprehensive a review of the available health data as possible, we submit these assessments should be incorporated into any risk assessments which will be used for regulatory control. This is particularly important in view of the fact that they are based upon human data rather than on laboratory animal results.

It can be seen from the above analysis that standard risk assessment methodology and the use of reported literature results lead to orders of magnitude over-estimates of the predicted risk from emissions of VCM from

BFG07552

500C9802

existing facilities. We recommend that these inconsistencies in the risk estimates be resolved if they are to be used as the basis for any proposed regulation.

TABLE 1. "RISK" PREDICTED FROM LMS MODEL
(using unit risk of 20×10^{-5} per ppb)

Occupational Exposure Scenario	Upper Bound on "Risk" (Cases Per 10,000)
400 ppm 30 years	9999
400 ppm 20 years	9995
300 ppm 30 years	9998
300 ppm 20 years	9964
200 ppm 30 years	9960
200 ppm 20 years	9770
100 ppm 30 years	9400
100 ppm 10 years	6090
100 ppm 5 years	3750

20863006

BFG07553

REFERENCES

1. California Air Resources Board (CARB), Draft Technical Support Document, Proposed Identification of Vinyl Chloride as a Toxic Air Contaminant. May, 1990.
2. Watanabe, P.G., McGowan, G.R., and Gehring, P.J. Fate of [^{14}C] Vinyl Chloride After Single Oral Administration in Rats. *Toxicology and Applied Pharmacology* 36, 339-352 (1976).
3. Gehring, P.J., Watanabe, P.G. and Park, C.N. Resolution of Dose-Response Toxicity Data for Chemicals Requiring Metabolic Activation: Example - Vinyl Chloride. *Toxicology and Applied Pharmacology* 44, 581-591, (1978).
4. Crump, K.S. Quantitative Assessment of Human Risk From Exposure to Carcinogens with Special Reference to Vinyl Chloride. Contract for Occupational Health and Safety Division, Ontario Ministry of Labour (1982).
5. EPA. Incorporation of Biological Information in Cancer Risk Assessment: Example Vinyl Chloride. Office of Environmental Health and Assessment, U.S. Environmental Protection Agency. EPA/600/d-87/188 (1987).
6. Gehring, P.J., Watanabe, P.G., and Park, C.N. Risk of Angiosarcoma in Workers Exposed to Vinyl Chloride as Predicted from Studies in Rats *Toxicology and Applied Pharmacology*. Vol. 49, No. 1 (June 15, 1979).
7. Anderson, M.W., Hoel, D.G., and Kaplan, N.L. A General Scheme for the Incorporation of Pharmacokinetics in Low-Dose Risk Estimation for Chemical Carcinogenesis: Example-Vinyl Chloride. *Toxicology and Applied Pharmacology* 55, 154-161 (1980).
8. Federal Register, Volume 51, Number 185, Wednesday, September 24, 1986.
9. Purchase, I.F.H., Stafford, J., and Paddle, G.M. Vinyl Chloride: An Assessment of the Risk of Occupational Exposure. *Fd. Chem. Toxic.* Vol. 25, No. 2, pp. 187-202, 1987.
10. Barr, J.T. Risk Assessment for Vinyl Chloride in Perspective. Presented at the 75th Annual Meeting of the Air Pollution Control Association, New Orleans, USA, (June 1982).
11. National Health Council of The Netherlands. A Scientific Basis for the Risk Assessment of Vinyl Chloride. *Regulatory Toxicology and Pharmacology* 7, 120-127 (1987).
12. Anderson, E.L., Ph.D. Risk Analysis in Environmental Health with Emphasis on Carcinogenesis". Harvard School of Public Health, September 18-20, 1984.
13. Doll, R. Effects of Exposure to Vinyl Chloride: An Assessment of the Evidence, *Scand J Work Environment Health* 14 (1988) 61-78.
14. Maltoni, C. and G. Lefemine. *Annals of N.Y. Academy of Sciences*. 246: 195-218 (1979).
15. Barnes, A.W. Vinyl Chloride and the Production of PVC. *Proc. R. Soc. Med.* 69: 277 (1976).

BFG07554

20863007

BFGoodrich

AN 4466

The BFGoodrich Company
3925 Embassy Parkway
Akron, Ohio 44313-1799
July 12, 1990

Mr. Ben Latimer
Dayco, Inc.
Balsam Road
P.O. Box 360
Waynesville, North Carolina 28786

SUBJECT: GEON 102EP - FDA STATUS

Dear Mr. Latimer:

Mr. Glen Schaaf asked that I write to you regarding the FDA status of Geon 102EP PVC resin. Geon 102EP is a homopolymer polyvinyl chloride (PVC) resin. Polyvinyl chloride is prior sanctioned for use in general food contact applications, both flexible and rigid. The prior sanction is based on an article by A. J. Lehman, from the FDA, published in the Journal of the Association of Food and Drug Officials, July, 1951. The current Good Manufacturing Practice (GMP) specifications for prior sanctioned PVC are a maximum volatility of 3.0% (1 hour at 105°C) and an inherent viscosity of not less than 0.35 by ASTM D-1243-79. Geon 102EP meets the GMP specifications for prior sanctioned PVC and therefore meets the current requirements of the FDA for general food contact applications.

PVC is also listed as an acceptable ingredient of food contact articles under 21CFR:

175.105	177.1200
175.300	177.2250
176.180	179.45
177.1010	

If you have any further questions, please call me at 216/374-3422.

Sincerely,

THE BFGOODRICH COMPANY

W. C. Bachtel

W. C. Bachtel
Toxicologist
Environmental Health and
Safety Management Systems

0712-2/jp

cc: Glen Schaaf - CL-OTM-3

BFG07555

20864001

July 9, 1990

To: Wally Bachtel
From: J.C. Kelley
Subject: NSF FORM

Attached is a NSF form from Jacuzzi Brothers and the recipe for Geon 87546 Natural 021.

Please complete the back of the NSF form and return it directly to NSF in the blue envelope provided.

Thanks for your help.


Joe C. Kelley

JCK/ga

Attachment

cc: Joe Gleason
R. Jeziorski
D. Kuharik
Day File
Desk File
NSF File

BFG07559

20865004

NEXT RESPONSE:
DC900016 RECIPE INQUIRY OK

NEXT KEY:
PF5-PROP PF6-RMKS PF9-SAFE PF10-INST

C103D326
C103F326 GEON PROD

BFGOODRICH GEON VINYL DIVISION
RECIPE INQUIRY

USERID: N50JCK3A
PTERMID: PV120013

PRODUCT NBR: 87546 000 0210 87546 NAT 021 LOC: 12 DEPT: 5667 ISSUE: 001

SBC: 13C5 EFFECTIVE DATE: 881004 INTERMEDIATE RM NBR:
TOTAL LBS RM: 114.000000 LBS PRODUCT: 114.000000 RECIPE TYPE:

PAGE 1 OF 1

SEQ	RAW MATL	DESCRIPTION	QUANTITY	LC	PERCENT	COMMENTS
110	961-000004	86	100.000000	12	87.7193	
210	942-00K026	DURASTRENGTH 20	8.000000		7.0175	
310	912-00S086	MARK 1900	2.000000		1.7544	
510	943-00L034	CA STEARATE-FUS	2.000000		1.7544	
520	943-00L035	EBS WAX POWDER	2.000000		1.7544	

NEXT RESPONSE:
DC900016 RECIPE INQUIRY OK

NEXT KEY:
PF5-PROP PF6-RMKS PF9-SAFE PF10-INST

BFG07560

20865005